[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595846":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":37,"locations":43,"responsibleParty":219,"collaborators":221,"id":224,"slug":225,"hasResults":226,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":226,"sex":232,"minAge":233,"maxAge":234,"enrollmentInfo":235,"targetDuration":32,"studyType":238,"phases":239,"briefSummary":241,"conditions":242,"keywords":244,"overallStatus":46,"whyStopped":32,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":255},{"fullName":5,"class":6},"Amgen","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Exploration","EXPERIMENTAL","Multiple dose levels of AB248 will be explored in combination with tarlatamab administered via intravenous (IV) infusion.",[13,14],"Drug: Tarlatamab","Drug: AB248",{"label":16,"type":10,"description":17,"interventionNames":18},"Dose Expansion","The dose expansion part will test tarlatamab in combination with the MTCD\u002Frecommended dose for expansion of AB248 identified in the dose exploration part.\n\nAn optional cohort may be opened based on emerging data to study tarlatamab in combination with AB248 at a lower dose than the MTCD\u002Frecommended dose for expansion or with an alternative dose regimen at a AB248 dose lower than or equal to MTCD\u002Frecommended dose for expansion.",[13,14],[20,28],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Tarlatamab","Administered as an IV infusion.",[16,9],[26,27],"AMG 757","Imdelltra",{"type":21,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"AB248","Administered either as an IV infusion followed by a flush or using a syringe pump without a flush.",[16,9],null,[34],{"name":35,"affiliation":5,"role":36},"MD","STUDY_DIRECTOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":32,"email":42},"Amgen Call Center","CONTACT","866-572-6436","medinfo@amgen.com",[44,58,68,78,88,98,108,118,127,137,146,156,166,176,181,185,194,204,213],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":32},"Banner MD Anderson Cancer Center","RECRUITING","Gilbert","Arizona","85234","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-111.78903,33.35283,{"lat":56,"lon":55},{"facility":59,"status":46,"city":60,"state":61,"zip":62,"country":50,"countryCode":51,"cosmosGeoPoint":63,"geoPoint":67,"contacts":32},"University of Southern California, Norris Comprehensive Cancer Center","Los Angeles","California","90033",{"type":53,"coordinates":64},[65,66],-118.24368,34.05223,{"lat":66,"lon":65},{"facility":69,"status":46,"city":70,"state":71,"zip":72,"country":50,"countryCode":51,"cosmosGeoPoint":73,"geoPoint":77,"contacts":32},"Moffitt Cancer Center","Tampa","Florida","33612",{"type":53,"coordinates":74},[75,76],-82.45843,27.94752,{"lat":76,"lon":75},{"facility":79,"status":46,"city":80,"state":81,"zip":82,"country":50,"countryCode":51,"cosmosGeoPoint":83,"geoPoint":87,"contacts":32},"Emory University","Atlanta","Georgia","30322",{"type":53,"coordinates":84},[85,86],-84.38798,33.749,{"lat":86,"lon":85},{"facility":89,"status":46,"city":90,"state":91,"zip":92,"country":50,"countryCode":51,"cosmosGeoPoint":93,"geoPoint":97,"contacts":32},"Norton Cancer Institute - Downtown","Louisville","Kentucky","40202-1703",{"type":53,"coordinates":94},[95,96],-85.75941,38.25424,{"lat":96,"lon":95},{"facility":99,"status":46,"city":100,"state":101,"zip":102,"country":50,"countryCode":51,"cosmosGeoPoint":103,"geoPoint":107,"contacts":32},"Dana-Farber Cancer Institute","Boston","Massachusetts","02215",{"type":53,"coordinates":104},[105,106],-71.05977,42.35843,{"lat":106,"lon":105},{"facility":109,"status":46,"city":110,"state":111,"zip":112,"country":50,"countryCode":51,"cosmosGeoPoint":113,"geoPoint":117,"contacts":32},"Siteman Cancer Center","St Louis","Missouri","63110",{"type":53,"coordinates":114},[115,116],-90.19789,38.62727,{"lat":116,"lon":115},{"facility":119,"status":46,"city":120,"state":120,"zip":121,"country":50,"countryCode":51,"cosmosGeoPoint":122,"geoPoint":126,"contacts":32},"Memorial Sloan Kettering Cancer Center","New York","10021",{"type":53,"coordinates":123},[124,125],-74.00597,40.71427,{"lat":125,"lon":124},{"facility":128,"status":46,"city":129,"state":130,"zip":131,"country":50,"countryCode":51,"cosmosGeoPoint":132,"geoPoint":136,"contacts":32},"Sidney Kimmel Cancer Center","Philadelphia","Pennsylvania","19107",{"type":53,"coordinates":133},[134,135],-75.16362,39.95238,{"lat":135,"lon":134},{"facility":138,"status":46,"city":139,"state":130,"zip":140,"country":50,"countryCode":51,"cosmosGeoPoint":141,"geoPoint":145,"contacts":32},"Allegheny General Hospital","Pittsburgh","15212",{"type":53,"coordinates":142},[143,144],-79.99589,40.44062,{"lat":144,"lon":143},{"facility":147,"status":46,"city":148,"state":149,"zip":150,"country":50,"countryCode":51,"cosmosGeoPoint":151,"geoPoint":155,"contacts":32},"Avera Cancer Institute","Sioux Falls","South Dakota","57105",{"type":53,"coordinates":152},[153,154],-96.72796,43.54369,{"lat":154,"lon":153},{"facility":157,"status":46,"city":158,"state":159,"zip":160,"country":50,"countryCode":51,"cosmosGeoPoint":161,"geoPoint":165,"contacts":32},"Baptist Cancer Center","Memphis","Tennessee","38120",{"type":53,"coordinates":162},[163,164],-90.04898,35.14953,{"lat":164,"lon":163},{"facility":167,"status":46,"city":168,"state":169,"zip":170,"country":50,"countryCode":51,"cosmosGeoPoint":171,"geoPoint":175,"contacts":32},"Swedish Cancer Institute Medical Oncology","Seattle","Washington","98109",{"type":53,"coordinates":172},[173,174],-122.33207,47.60621,{"lat":174,"lon":173},{"facility":177,"status":46,"city":178,"state":32,"zip":179,"country":180,"countryCode":32,"cosmosGeoPoint":32,"geoPoint":32,"contacts":32},"Chungbuk National University Hospital","Cheongju Chungbuk","28644","South Korea",{"facility":182,"status":46,"city":183,"state":32,"zip":184,"country":180,"countryCode":32,"cosmosGeoPoint":32,"geoPoint":32,"contacts":32},"Seoul National University Bundang Hospital","Seongnam-si, Gyeonggi-do","13620",{"facility":186,"status":46,"city":187,"state":32,"zip":188,"country":180,"countryCode":32,"cosmosGeoPoint":189,"geoPoint":193,"contacts":32},"Severance Hospital Yonsei University Health System","Seoul","03722",{"type":53,"coordinates":190},[191,192],126.9784,37.566,{"lat":192,"lon":191},{"facility":195,"status":46,"city":196,"state":32,"zip":197,"country":198,"countryCode":32,"cosmosGeoPoint":199,"geoPoint":203,"contacts":32},"Adana Sehir Egitim ve Arastirma Hastanesi","Adana","01370","Turkey (Türkiye)",{"type":53,"coordinates":200},[201,202],35.32531,36.98615,{"lat":202,"lon":201},{"facility":205,"status":46,"city":206,"state":32,"zip":207,"country":198,"countryCode":32,"cosmosGeoPoint":208,"geoPoint":212,"contacts":32},"Hacettepe Universitesi Tip Fakultesi Hastanesi","Ankara","06230",{"type":53,"coordinates":209},[210,211],32.85427,39.91987,{"lat":211,"lon":210},{"facility":214,"status":46,"city":206,"state":32,"zip":215,"country":198,"countryCode":32,"cosmosGeoPoint":216,"geoPoint":218,"contacts":32},"Ankara Bilkent Sehir Hastanesi","06800",{"type":53,"coordinates":217},[210,211],{"lat":211,"lon":210},{"type":220,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[222],{"name":223,"class":6},"Asher Biotherapeutics, Inc.","100595846","phase-1-a-study-of-tarlatamab-in-combination-with-ab248-in-participants-with-extensive-stage-small-cell-lung-cancer-dellphi-311-100595846",false,"NCT07037758","A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)","A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)","DeLLphi-311","Inclusion Criteria:\n\n1. Participant has provided informed consent before initiation of any study-specific activities\u002Fprocedures.\n2. Participants ≥ 18 years (or ≥ legal age within the country if it is older than 18 years) at the time of signing the informed consent.\n3. Participants with histologically or cytologically confirmed ES-SCLC that has progressed or recurred following at least 1 line of anti-cancer therapy for ES-SCLC.\n4. Participants must have at least 1 measurable lesion as defined by RECIST 1.1 within 21-day screening period, not previously irradiated.\n5. Participants must have adequate organ function (hematological, coagulation, cardiac, pulmonary, kidney, and liver).\n6. Participants must submit a fresh tumor biopsy at screening unless a new biopsy cannot be performed safely or is infeasible. Participants who cannot provide fresh tissue may provide archival tissue that was collected after last anticancer therapy.\n\nExclusion Criteria:\n\n1. Symptomatic central nervous system (CNS) metastases.\n2. Participants with brain metastases may be eligible if criteria defined in the protocol are met.\n3. Prior therapy with any delta-like ligand 3 (DLL3)-directed therapy (including tarlatamab).\n4. Prior interleukin (IL)-2, IL-7 or IL-15 targeted therapy.\n5. Baseline (at rest) requirement of supplemental oxygen.","ALL","18 Years","90 Years",{"count":236,"type":237},380,"ESTIMATED","INTERVENTIONAL",[240],"PHASE1","The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248.\n\nThe primary objective for dose exploration only is to determine the recommended dose for expansion and\u002For maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.",[243],"Extensive Stage Small Cell Lung Cancer",[245,22,26,29,27],"ES-SCLC","2026-05-27",{"date":248,"type":249},"2026-05-29","ACTUAL",{"date":251,"type":249},"2025-09-16",{"date":253,"type":237},"2031-01-18",{"name":5,"class":6},19]